

Resource Summary Report

Generated by [NIF](#) on Sep 10, 2026

NCI-H660

RRID:CVCL_1576

Type: Cell Line

Proper Citation

RRID:CVCL_1576

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1576

Proper Citation: RRID:CVCL_1576

Description: Cell line NCI-H660 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Prostate small cell carcinoma

Defining Citation: [PMID:1563005](#), [PMID:2569043](#), [PMID:2985257](#), [PMID:8806092](#), [PMID:8806103](#), [PMID:11030152](#), [PMID:11304728](#), [PMID:14518029](#), [PMID:15643172](#), [PMID:17401460](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23671654](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27247353](#), [PMID:27397505](#), [PMID:28766886](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:32586373](#), [PMID:35839778](#)

Comments: Caution: Was originally published as originating from a small cell lung carcinoma (PubMed=2985257), but was later shown to originate from a prostate small cell carcinoma (PubMed=2569043)., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H660

Synonyms: H660, H-660, NCIH660, NCI660

Cross References: BTO:BTO_0001970, CLO:CLO_0008102, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5813, BioSample:SAMN03473052, BioSample:SAMN10988121, cancercellines:CVCL_1576,

Cell_Model_Passport:SIDM01123, Cosmic:877360, Cosmic:1021869, Cosmic:1043331, Cosmic:1075272, Cosmic:1689713, Cosmic:2651769, Cosmic:2669168, Cosmic-CLP:1330975, DepMap:ACH-000177, EGA:EGAS00001000978, GEO:GSM482672, GEO:GSM648822, GEO:GSM887440, GEO:GSM888520, GEO:GSM1670256, GEO:GSM1887911, GEO:GSM1887993, IARC_TP53:21084, IARC_TP53:21725, IGRhCellID:NCIH660, LiGeA:CCL_659, PharmacDB:NCIH660_1126_2019, PRIDE:PXD030304, Progenetix:CVCL_1576, Wikidata:Q54908097

ID: CVCL_1576

Record Creation Time: 20220427T220840+0000

Record Last Update: 20260905T181246+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H660.

No alerts have been found for NCI-H660.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 22 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Cao Y, et al. (2026) Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumors. *Cell reports. Medicine*, 7(4), 102695.

Subramani E, et al. (2026) Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers. *iScience*, 29(6), 116184.

Ji Y, et al. (2026) Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming. *Cancer discovery*, 16(4), 760.

Derderian S, et al. (2025) Clinical significance of stratifying prostate cancer patients through specific circulating genes. *Molecular oncology*, 19(5), 1310.

Kumaraswamy A, et al. (2025) LSD1+8a is an RNA biomarker of neuroendocrine prostate cancer. *Neoplasia (New York, N.Y.)*, 63, 101151.

Ku SY, et al. (2025) Preclinical activity of the DLL3-targeted T cell engager MK-6070 in neuroendocrine prostate cancer. *Molecular cancer therapeutics*.

Zhang D, et al. (2024) Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy. *EBioMedicine*, 105, 105212.

Liu S, et al. (2024) UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas. *Cell reports. Medicine*, 5(2), 101381.

Sulsenti R, et al. (2024) Intracellular Osteopontin Promotes the Release of TNF α by Mast Cells to Restrain Neuroendocrine Prostate Cancer. *Cancer immunology research*, 12(9), 1147.

Manzar N, et al. (2024) An integrative proteomics approach identifies tyrosine kinase KIT as a therapeutic target for SPINK1-positive prostate cancer. *iScience*, 27(3), 108794.

Awad D, et al. (2024) Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity. *Cancer research*, 84(5), 703.

Wang Z, et al. (2024) Molecular subtypes of neuroendocrine carcinomas: A cross-tissue classification framework based on five transcriptional regulators. *Cancer cell*, 42(6), 1106.

Wang J, et al. (2024) Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancer. *Cell reports. Medicine*, 5(2), 101388.

Yang C, et al. (2023) Induction of PARP7 Creates a Vulnerability for Growth Inhibition by RBN2397 in Prostate Cancer Cells. *Cancer research communications*, 3(4), 592.

Drazdauskienė U, et al. (2023) Fusion sequencing via terminator-assisted synthesis (FTAS-seq) identifies TMPRSS2 fusion partners in prostate cancer. *Molecular oncology*, 17(6), 993.

Zhang A, et al. (2023) Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers. *Cancer research communications*, 3(11), 2358.

Al-Nakouzi N, et al. (2022) Reformation of the chondroitin sulfate glycocalyx enables progression of AR-independent prostate cancer. *Nature communications*, 13(1), 4760.

Yu L, et al. (2022) Increased Expression and Altered Cellular Localization of Fibroblast Growth Factor Receptor-Like 1 (FGFRL1) Are Associated with Prostate Cancer Progression. *Cancers*, 14(2).

Pearson JD, et al. (2021) Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. *Cancer cell*, 39(8), 1115.

Reina-Campos M, et al. (2019) Increased Serine and One-Carbon Pathway Metabolism by PKC δ Deficiency Promotes Neuroendocrine Prostate Cancer. *Cancer cell*, 35(3), 385.